Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

Two of China’s most prominent immuno-oncology companies made moves this week to bolster their CAR T cell therapy pipelines: one via a deal and the other with a financing.

Innovent Biologics Inc. (HKSE:1801) has acquired non-exclusive access to two technologies from Roche (SIX:ROG; OTCQX:RHHBY) -- one for universal CAR Ts and the other for 2:1 T cell bispecific antibodies -- for discovering and developing treatments for hematologic and solid cancers...